echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Treatment of multi-drug-resistant bacterial pneumonia New antibiotics are expected to be approved this year

    Treatment of multi-drug-resistant bacterial pneumonia New antibiotics are expected to be approved this year

    • Last Update: 2020-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hospital-acquired pneumonia caused by Gram-negative bacteria(including Ecoli, Gyeeloba, and Kiwi-variant bacteria) is a serious bacterial infection that often occurs in critical and susceptible hospital populationsAntibiotic resistance is associated with the resistance mechanism stoicine bacteria that produce ultra-broad-spectrum beta-lactamase and carbon-amynosThe growing problem of bacterial resistance has led to an increase in morbidity and mortalitySo doctors and patients have been looking forward to the emergence of innovative antimicrobial therapiesSaltfield's cefiderocol is a new iron carrier cephalosporin antibiotic drugIt has a unique mechanism that not only allows the drug to pass through the cell membranes of Gram-negative bacteria, including multidrug-resistant (MDR) strains, but also enables cefidero to reach a high concentration within the cell perimeter, bind smoothly to the receptors, and inhibit cell wall synthesisIn addition, it can fight a variety of beta-lactamase classesPrevious studies have shown that cefiderocol has good drug efficacy in vitro against a variety of gram-negative bacteria, including anti-carbon ilostenetic bacteriaCefiderocol Molecular Structure (Photo: User: Edgar181 (Public Domain))the data released this time comes from a double-blind, randomized 3-phase non-performance testThe results showed that cefiderocol achieved a non-effect severance in the 14-day all-cause mortality rate in the patient group of improved intent therapy (MITT) compared to the active control group who received high doses of meropenem treatment - 12.4% in the cefiderocol group and 11.6% in the control groupIn the microbiology-assessable patient population, the data was 12.4% (cefiderocol) to 13% (control group)In addition, cefiderocol reached several key secondary endpoints of the experiment"APEKS-NP trial data demonstrate the potential of cefiderocol to be a treatment option for patients with acquired pneumonia in incurable hospitals," said DrTsutae Denata, Chief Medical Officer, "At the moment, while new antibiotics are used to treat the disease, they do not solve all the problems of drug-resistant Gram-negative pathogens." Clinicians urgently need new treatments to overcome multiple drug resistance and help patients treat diseasesReferences: Sionogi Reports Positive Results From Cefiderocol Phase III Study In Adults with Nosocomial Pneumonia Caused by Gram-Negatives, Horead October 09, 2019, https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.